Pages that link to "Q33501657"
Jump to navigation
Jump to search
The following pages link to Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study (Q33501657):
Displaying 50 items.
- Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma (Q24791107) (← links)
- Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer? (Q26742047) (← links)
- Adoptive immunotherapy against ovarian cancer (Q26748905) (← links)
- Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives (Q26751280) (← links)
- Profile of bevacizumab and its potential in the treatment of cervical cancer (Q26774168) (← links)
- Advanced ovarian cancer: what should be the standard of care? (Q27852053) (← links)
- Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study (Q28209431) (← links)
- Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics (Q30444706) (← links)
- Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. (Q31050729) (← links)
- Use of systemic therapy in women with recurrent ovarian cancer--development of a national clinical practice guideline. (Q33284493) (← links)
- Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer (Q33333233) (← links)
- Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies: A Gynecologic Oncology Group study (Q33345422) (← links)
- Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval. (Q33347044) (← links)
- Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study (Q33347651) (← links)
- Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study (Q33362775) (← links)
- Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study (Q33365080) (← links)
- Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer (Q33366785) (← links)
- Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up (Q33369422) (← links)
- Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group (Q33372563) (← links)
- Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer (Q33379246) (← links)
- Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer (Q33380764) (← links)
- Phase II study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer (Q33386456) (← links)
- Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer (Q33389636) (← links)
- Phase II Clinical Study of the Combination Chemotherapy Regimen of Irinotecan Plus Oral Etoposide for the Treatment of Recurrent Ovarian Cancer (Tohoku Gynecologic Cancer Unit 101 Group Study) (Q33394205) (← links)
- Feasibility of Intravenous Gemcitabine and an Intraperitoneal Platinum Agent in the Treatment of Ovarian Cancer (Q33396173) (← links)
- Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503). (Q33419022) (← links)
- Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence (Q33680243) (← links)
- Chemotherapy for ovarian cancer: current concepts (Q33742794) (← links)
- Up date in the management of advanced ovarian carcinoma (Q33787474) (← links)
- Role of chemotherapy in relapsed ovarian cancer (Q33816593) (← links)
- Oral etoposide for the treatment of recurrent ovarian cancer (Q33859951) (← links)
- Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issues (Q33859957) (← links)
- Current management of epithelial ovarian carcinoma: a review (Q33959810) (← links)
- Drug therapy for gynaecological cancer in older women (Q33996151) (← links)
- Major Clinical Impact of Platinum-Based Chemotherapy in a Patient with a Borderline Ovarian Cancer (Q34038021) (← links)
- Salvage therapy for ovarian cancer (Q34107675) (← links)
- Current treatment for ovarian cancer (Q34240764) (← links)
- Epithelial ovarian cancer: A case report (Q34292286) (← links)
- Phase 1/2 Study of Atrasentan Combined with Pegylated Liposomal Doxorubicin in Platinum-Resistant Recurrent Ovarian Cancer (Q34300629) (← links)
- A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology (Q34387999) (← links)
- Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma (Q34453268) (← links)
- Treatment of advanced ovarian cancer (Q34462125) (← links)
- Caelyx: phase II studies in ovarian cancer (Q34462134) (← links)
- Clinical trials and progress with paclitaxel in ovarian cancer (Q34510070) (← links)
- Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer (Q34528724) (← links)
- Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers (Q34616645) (← links)
- Advanced ovarian cancer (Q34677693) (← links)
- Epithelial ovarian cancer (Q34677827) (← links)
- Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer (Q34734502) (← links)
- Ovarian cancer: progress and continuing controversies in management (Q34783604) (← links)